Keros Therapeutics, Inc (KROS)

Etorro trading 970x250
Keros Therapeutics, Inc (KROS) Logo

About Keros Therapeutics, Inc

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company’s lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, as well as for the treatment of fibrodysplasia ossificans progressiva, or FOP, and is currently in a Phase 1 clinical trial; and KER-012 being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension, or PAH. The company was founded in 2015 and is headquartered in Lexington, Massachusetts. Address: 99 Hayden Avenue, Lexington, MA, United States, 02421

Keros Therapeutics, Inc News and around…

Latest news about Keros Therapeutics, Inc (KROS) common stock and company :

LABU's Underlying Holdings Could Mean 72% Gain Potential
14 Oct, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Daily S&P Biotech Bull 3X Shares ETF (LABU), we found that the implied analyst target price for the ETF based upon its underlying holdings is $93.38 per unit.

Keros Therapeutics Insider Sold $510K In Company Stock
06 Oct, 2021 Yahoo! Finance

Julius Knowles, Director at Keros Therapeutics (NASDAQ:KROS), made a large insider sell on October 5, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Tuesday showed that Knowles sold 12,686 shares of Keros Therapeutics at prices ranging from $40.03 to $40.16. The total transaction amounted to $508,755. Knowles still owns a total of 302,958 shares of Keros Therapeutics worth, $11,936,545. Keros Therapeutics shares are trading down

Keros Therapeutics Presents Results from a Preclinical Study of RKER-012 in Pulmonary Arterial Hypertension-Associated Bone Loss at the American Society for Bone and Mineral Research 2021 Annual Meeting
04 Oct, 2021 Yahoo! Finance

LEXINGTON, Mass., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, today announced that it presented results from a preclinical study of KER-012 at the American Society for Bone and Mineral Research (ASBMR) 2021 Annual Meeting held October

50 Biggest Movers From Yesterday
28 Sep, 2021 FinancialContent

Gainers Red Cat Holdings, Inc. (NASDAQ: RCAT) shares surged 50% to close at $3.60 on Monday after the company said its subsidiary, ...

12 Health Care Stocks Moving In Monday's Intraday Session
27 Sep, 2021 FinancialContent

Gainers Keros Therapeutics (NASDAQ:KROS) stock moved upwards by 26.51% to $41.75 during Monday's regular session. ...

31 Stocks Moving In Monday's Mid-Day Session
27 Sep, 2021 FinancialContent

Gainers Red Cat Holdings, Inc. (NASDAQ: RCAT) shares jumped 54.1% to $3.6998 after the company said its subsidiary, Skypersonic, ...

12 Health Care Stocks Moving In Monday's Pre-Market Session
27 Sep, 2021 FinancialContent

Gainers Syndax Pharmaceuticals (NASDAQ:SNDX) shares moved upwards by 8.94% to $20.48 during Monday's pre-market ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
27 Sep, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Welcome back, investor! We're starting off the week with a dive into the biggest pre-market stock movers for Monday morning! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Analyst Who Found Microsoft at $0.38 Names #1 Pick for the AI Boom America’s #1 EV Stock Still Flying Under the Radar

20 Stocks Moving in Monday's Pre-Market Session
27 Sep, 2021 FinancialContent

Gainers Puhui Wealth Investment Management Co., Ltd. (NASDAQ: PHCF) rose 49% to $3.65 in pre-market trading. Paltalk, Inc. ...

The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO Departs
22 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data
21 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

VTHR's Underlying Holdings Imply 10% Gain Potential
13 Sep, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Russell 3000 ETF (VTHR), we found that the implied analyst target price for the ETF based upon its underlying holdings is $225.64 per unit.

Keros Therapeutics to Participate in Two Upcoming Healthcare Conferences
02 Sep, 2021 FinancialContent
The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data
20 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck
19 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
18 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
17 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Stocks That Hit 52-Week Lows On Monday
16 Aug, 2021 FinancialContent

On Monday morning, 207 companies hit new 52-week lows. Intriguing Points: The largest company in terms of market cap ...

Keros Therapeutics Reports Recent Business Highlights and Second Quarter 2021 Financial Results
05 Aug, 2021 FinancialContent
Keros Therapeutics Appoints Simon Cooper, M.B.B.S. as Chief Medical Officer
02 Aug, 2021 FinancialContent
Keros Therapeutics Enters Oversold Territory (KROS)
22 Jul, 2021 FinancialContent

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

Sum Up The Parts: PBSM Could Be Worth $44
12 Jul, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco PureBeta MSCI USA Small Cap ETF (PBSM), we found that the implied analyst target price for the ETF based upon its underlying holdings is $44.26 per unit.

Keros Therapeutics (NASDAQ:KROS) Is In A Good Position To Deliver On Growth Plans
07 Jul, 2021 Yahoo! Finance

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Keros Therapeutics Becomes Oversold (KROS)
01 Jul, 2021 FinancialContent

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

45 Biggest Movers From Yesterday
24 Jun, 2021 FinancialContent

Gainers Entera Bio Ltd. (NASDAQ: ENTX) shares surged 44.8% to close at $6.50 on Wednesday after the company reported topline ...

12 Health Care Stocks Moving In Wednesday's Intraday Session
23 Jun, 2021 FinancialContent

Gainers Orphazyme (NASDAQ:ORPH) shares moved upwards by 32.66% to $7.92 during Wednesday's regular session. As of ...

Mid-Day Market Update: Crude Oil Rises Over 1%; Gemini Therapeutics Shares Slide
23 Jun, 2021 FinancialContent

Midway through trading Wednesday, the Dow traded up 0.01% to 33,948.64 while the NASDAQ rose 0.19% to 14,280.41. The S&P also rose, ...

31 Stocks Moving In Wednesday's Mid-Day Session
23 Jun, 2021 FinancialContent

Gainers Entera Bio Ltd. (NASDAQ: ENTX) shares jumped 58% to $7.09 after the company reported topline Phase 2 bone mineral density ...

Keros Therapeutics Announces Preliminary Results from its Phase 2 Clinical Trial Evaluating KER-050 in Patients with Myelodysplastic Syndromes
22 Jun, 2021 FinancialContent
Keros Therapeutics Presents Preclinical Data from ALK2 and KER-050 Hematology Programs at the European Hematology Association EHA2021 Virtual Congress
11 Jun, 2021 FinancialContent

Keros Therapeutics, Inc (KROS) is a NASDAQ Common Stock listed in , ,

970x250